Comparison of clinical efficacy and safety of original and generic forms of etoricoxib in patients with knee osteoarthritis
Authors:
- M.O. KorzhMKM.O. Korzh
- O.B. IaremenkoOIO.B. Iaremenko
- A.S. MusiienkoAMA.S. Musiienko
- V.A. FilipenkoV.A. Filipenko
- D.I. KoliadenkoDKD.I. Koliadenko
- Z.A. ArutiunianZAZ.A. Arutiunian
- A.V. IniushynaAIA.V. Iniushyna
- D.V. DobrianskiyDDD.V. Dobrianskiy
- D.YU. KuryloDKD.YU. Kurylo
- A.O. SydorovaASA.O. Sydorova
- N.V. GrygorievaNGN.V. Grygorieva
Open Access
- 29 March 2024
- journal article
- research article
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 14 (1) , 21-28
Abstract
Background. Nonsteroidal anti-inflammatory drugs (NSAIDs) are an important drug class for the treatment of osteoarthritis (OA). Despite existing studies on the bioequivalence of original and generic NSAIDs, comparative studies related to their clinical efficacy and safety are limited. The purpose of the study was to compare the clinical efficacy and safety of the original and generic forms of etoricoxib in patients with knee OA. Materials and methods. In an open, comparative, randomized, multicenter study, 150 patients with knee OA were examined: group I — 50 persons who received the original etoricoxib (60 mg/d for 10 days), groups II and III — 50 subjects each who received generic etoricoxib (60 mg/d for 10 days). The effectiveness of the treatment was evaluated using the four-component visual analog scale (VAS), the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and the Lequesne index before the start of therapy and on the 10th day. Assessment of tolerability and safety was studied by controlling adverse events based on clinical and laboratory indicators. Results. The use of the original and generic forms of etoricoxib in patients with knee OA led to positive dynamics of pain syndrome and functional activity, while the dynamics of indices were the greatest in the case of using the original etoricoxib (VAS: group I — 50.0 [35.4–60.0] %, group II — 29.1 [16.7–55.0] % and III — 28.6 [14.3–33.3] %). The most pronounced positive dynamics of the pain syndrome against the background of taking the original etoricoxib compared to the generic forms was registered in the subgroup of patients with severe knee pain (VAS > 60 mm). The use of all forms of etoricoxib was safe and did not lead to serious clinical side effects or clinically significant changes in laboratory blood parameters. The highest rates of satisfaction with the treatment by patients and physicians were observed in the case of the original etoricoxib use. Conclusions. The use of the original etoricoxib in patients with knee OA, especially in the presence of severe pain syndrome (VAS > 60 mm) is the most justified and safe.Keywords
This publication has 22 references indexed in Scilit:
- Prevalence Trends of Site‐Specific Osteoarthritis From 1990 to 2019: Findings From the Global Burden of Disease Study 2019Arthritis & Rheumatology, 2022
- An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)Seminars in Arthritis and Rheumatism, 2019
- OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritisOsteoarthritis and Cartilage, 2019
- OsteoarthritisThe Lancet, 2019
- Comparative effectiveness of oral pharmacologic interventions for knee osteoarthritis: A network meta-analysisModern Rheumatology, 2018
- Fourteen days of etoricoxib 60 mg improves pain, hyperalgesia and physical function in individuals with knee osteoarthritis: a randomized controlled trialOsteoarthritis and Cartilage, 2017
- Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal InjuryMedicine, 2015
- Osteoarthritis in Europe: impact on health status, work productivity and use of pharmacotherapies in five European countriesRheumatology, 2014
- Review article: COX‐II inhibitors—a new generation of safer NSAIDs?Alimentary Pharmacology & Therapeutics, 1997
- A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymesTrends in Pharmacological Sciences, 1997